Suppr超能文献

光疗后新生儿胆红素反弹:严重高胆红素血症的一个潜在原因。

Post-phototherapy neonatal bilirubin rebound: a potential cause of significant hyperbilirubinaemia.

作者信息

Kaplan M, Kaplan E, Hammerman C, Algur N, Bromiker R, Schimmel M S, Eidelman A I

机构信息

Department of Neonatology, Shaare Zedek Medical Center, Jerusalem, Israel.

出版信息

Arch Dis Child. 2006 Jan;91(1):31-4. doi: 10.1136/adc.2005.081224. Epub 2005 Oct 13.

Abstract

AIM

To determine the incidence of post-phototherapy neonatal plasma total bilirubin (PTB) rebound.

METHODS

A prospective clinical survey was performed on 226 term and near-term neonates treated with phototherapy in the well baby nursery of the Shaare Zedek Medical Center from January 2001 to September 2002. Neonates were tested for PTB 24 hours (between 12 and 36 hours) after discontinuation of phototherapy, with additional testing as clinically indicated. The main outcome measure, significant bilirubin rebound, was defined as a post-phototherapy PTB > or =256 micromol/l. Phototherapy was not reinstituted in all cases of rebound, but rather according to clinical indications.

RESULTS

A total of 30 (13.3%) neonates developed significant rebound (mean (SD) PTB 287 (27) micromol/l, upper range 351 micromol/l). Twenty two of these (73%) were retreated with phototherapy at mean PTB 296 (29) micromol/l. Multiple logistic regression analysis showed significant risk for aetiological risk factors including positive direct Coombs test (odds ratio 2.44, 95% CI 1.25 to 4.74) and gestational age <37 weeks (odds ratio 3.21, 95% CI 1.29 to 7.96). A greater number of neonates rebounded among those in whom phototherapy was commenced < or =72 hours (26/152, 17%) compared with >72 hours (4/74, 5.4%) (odds ratio 3.61, 95% CI 1.21 to 10.77).

CONCLUSION

Post-phototherapy neonatal bilirubin rebound to clinically significant levels may occur, especially in cases of prematurity, direct Coombs test positivity, and those treated < or =72 hours. These risk factors should be taken into account when planning post-phototherapy follow up.

摘要

目的

确定光疗后新生儿血浆总胆红素(PTB)反弹的发生率。

方法

对2001年1月至2002年9月在沙雷泽德克医疗中心健康婴儿保育室接受光疗的226例足月儿和近足月儿进行前瞻性临床调查。光疗停止后24小时(12至36小时之间)对新生儿进行PTB检测,并根据临床指征进行额外检测。主要观察指标,即显著胆红素反弹,定义为光疗后PTB≥256微摩尔/升。并非所有反弹病例均重新进行光疗,而是根据临床指征决定。

结果

共有30例(13.3%)新生儿出现显著反弹(平均(标准差)PTB为287(27)微摩尔/升,上限为351微摩尔/升)。其中22例(73%)在平均PTB为296(29)微摩尔/升时重新接受光疗。多因素logistic回归分析显示,病因风险因素包括直接抗人球蛋白试验阳性(比值比2.44,95%可信区间1.25至4.74)和胎龄<37周(比值比3.21,95%可信区间1.29至7.96)存在显著风险。光疗开始时间≤72小时的新生儿中反弹的人数更多(26/152,17%),而光疗开始时间>72小时的新生儿中反弹人数为4/74(5.4%)(比值比3.61,95%可信区间1.21至10.77)。

结论

光疗后新生儿胆红素可能反弹至临床显著水平,尤其是在早产、直接抗人球蛋白试验阳性以及光疗开始时间≤72小时的病例中。在计划光疗后随访时应考虑这些风险因素。

相似文献

1
Post-phototherapy neonatal bilirubin rebound: a potential cause of significant hyperbilirubinaemia.
Arch Dis Child. 2006 Jan;91(1):31-4. doi: 10.1136/adc.2005.081224. Epub 2005 Oct 13.
3
Rebound in serum bilirubin level following intensive phototherapy.
Arch Pediatr Adolesc Med. 2002 Jul;156(7):669-72. doi: 10.1001/archpedi.156.7.669.
5
Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more.
N Engl J Med. 2006 May 4;354(18):1889-900. doi: 10.1056/NEJMoa054244.
7
Incidence and risk factors of post-phototherapy neonatal rebound hyperbilirubinemia.
World J Pediatr. 2018 Aug;14(4):350-356. doi: 10.1007/s12519-018-0119-9. Epub 2018 Feb 20.
8
Skin bilirubin measurement during phototherapy in preterm and term newborn infants.
Early Hum Dev. 2009 Aug;85(8):537-40. doi: 10.1016/j.earlhumdev.2009.05.010. Epub 2009 May 29.
10
Glucose-6-phosphate dehydrogenase deficiency in neonatal hyperbilirubinaemia: Hacettepe experıence.
J Paediatr Child Health. 2013 May;49(5):399-402. doi: 10.1111/jpc.12193. Epub 2013 Apr 11.

引用本文的文献

1
Evaluation of total serum bilirubin thresholds for discontinuing phototherapy in jaundiced neonates: a randomized study.
Clin Exp Pediatr. 2025 Jul;68(7):539-545. doi: 10.3345/cep.2024.01249. Epub 2025 Feb 26.
3
The development and validation of a predictive model for neonatal phototherapy outcome using admission indicators.
Front Pediatr. 2022 Oct 11;10:745423. doi: 10.3389/fped.2022.745423. eCollection 2022.
4
Predictive Models for Neonatal Follow-Up Serum Bilirubin: Model Development and Validation.
JMIR Med Inform. 2020 Oct 29;8(10):e21222. doi: 10.2196/21222.
7
Incidence and risk factors of post-phototherapy neonatal rebound hyperbilirubinemia.
World J Pediatr. 2018 Aug;14(4):350-356. doi: 10.1007/s12519-018-0119-9. Epub 2018 Feb 20.
9
Efficacy of phototherapy for neonatal jaundice is increased by the use of low-cost white reflecting curtains.
Arch Dis Child Fetal Neonatal Ed. 2006 Nov;91(6):F439-42. doi: 10.1136/adc.2006.095687. Epub 2006 Jul 28.
10
Rebound bilirubin: on what should the decision to recommence phototherapy be based?
Arch Dis Child. 2006 Jul;91(7):623; author reply 16223746.

本文引用的文献

2
Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.
Pediatrics. 2004 Jul;114(1):297-316. doi: 10.1542/peds.114.1.297.
4
Rebound in serum bilirubin level following intensive phototherapy.
Arch Pediatr Adolesc Med. 2002 Jul;156(7):669-72. doi: 10.1001/archpedi.156.7.669.
5
Bilirubin rebound.
J Pediatr. 1999 Oct;135(4):531-2. doi: 10.1016/s0022-3476(99)70186-1.
7
Rebound bilirubin levels in infants receiving phototherapy.
J Pediatr. 1998 Nov;133(5):705-7. doi: 10.1016/s0022-3476(98)70117-9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验